Monophosphoryl Lipid A Enhances Efficacy of a Francisella tularensis LVS-Catanionic Nanoparticle Subunit Vaccine against F. tularensis Schu S4 Challenge by Augmenting both Humoral and Cellular Immunity

Francisella tularensis , a bacterial biothreat agent, has no approved vaccine in the USA. Previously, we showed that incorporating lysates from partially attenuated F. tularensis LVS or fully virulent F. tularensis Schu S4 strains into catanionic surfactant vesicle (V) nanoparticles (LVS-V and Schu S4-V, respectively) protected fully against F. tularensis LVS intraperitoneal (i.p.) challenge in mice. However, we achieved only partial protection against F. tularensis Schu S4 intranasal (i.n.) challenge, even when employing heterologous prime/boost immunization strategies. We now extend these findings to show that both LVS-V and Schu S4-V immunization (i.p./i.p.) elicited similarly high titers of anti- F. tularensis IgG, and that the titers could be further increased by adding monophosphoryl lipid A (MPL), a nontoxic TLR4 adjuvant that is included in several FDA-approved vaccines. LVS-V + MPL immune sera also detected more F. tularensis antigens than LVS-V immune sera and, after passive transfer to naive mice, significantly delayed the time to death against F. tularensis Schu S4 subcutaneous (s.c.), but not i.n. challenge. Active immunization with LVS-V + MPL (i.p./i.p.) also increased the frequency of IFN-γ-secreting activated helper T cells, IFN-γ production, and the ability of splenocytes to control intra-macrophage F. tularensis LVS replication ex vivo . Active LVS-V + MPL immunization via heterologous routes (i.p./i.n.) significantly elevated IgA and IgG levels in bronchoalveolar lavage fluid (BALf) and significantly enhanced protection against i.n. F. tularensis Schu S4 challenge (to ∼60%). These data represent a significant step forward in the development of a subunit vaccine against the highly virulent Type A strains.